The UK Biobank has completed the world’s largest study of key molecular compounds in the blood, analyzing data collected from 500,000 volunteers. As a result of this data, scientists will soon be able to create simple tests that can identify the first signs of disease more than a decade before symptoms appear.
The innovation developed by British scientists represents a fundamental shift in healthcare: it will move the focus from reactive treatment (after symptoms emerge) to proactive prevention (identifying risks at an early stage).
UK Biobank, in partnership with Nightingale Health, studied and quantified approximately 250 different metabolic compounds. These substances include essential components for the body—proteins, sugars, fats, and nitrogenous waste products, such as urea.
These compounds are the result of our body’s functioning: how we break down food, how we use energy, and how we regenerate tissues. The combination of these compounds creates a detailed and dynamic “picture,” or metabolic profile, of each person’s physiological state.
Using this profile, scientists can predict the risk of disease development. They compare metabolic data with the medical histories of other patients (when they were diagnosed and what treatment they received) and official data on causes of death. Through this comparison, scientists find links between the metabolic profile and the development of pathologies such as diabetes, cardiovascular diseases, cancer, and dementia.
The metabolic profile changes when organ function is impaired: for example, a damaged kidney increases urea and creatinine, while cancer increases glucose uptake. The metabolic profile obtained by scientists is unique because metabolites are influenced not only by genetics but also by environmental factors—diet, physical activity, pollution, and stress. All this means that metabolic profiles describe both genetic predisposition and the effects of environmental exposure.
Although scientists previously had a limited amount of UK Biobank metabolic profiles available, the full dataset from 500,000 volunteers is a major breakthrough. It allows for the creation of much more reliable early-detection tests for a wider spectrum of diseases. For example, metabolic profiles are already being used to predict the risk of dementia, including rare neurodegenerative diseases, 10-15 years in advance.
Researchers at the University of Oxford have already used this data to identify differences in the aging process and the development of age-related diseases between men and women, and a study is planned to examine how sex affects the effectiveness of medications. The study of metabolites is considered a powerful way to discover new early warning signs of disease, better understand disease development, and evaluate the effectiveness of treatments.
